Ivars Petrovskis
University of Latvia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ivars Petrovskis.
FEBS Letters | 2000
Indulis Cielens; Velta Ose; Ivars Petrovskis; Anna Strelnikova; Regina Renhofa; Tatyana Kozlovska; Paul Pumpens
Icosahedral virus‐like particles (VLPs) of RNA phage Qβ are stabilized by four disulfide bonds of cysteine residues 74 and 80 within the loop between β‐strands F and G (FG loop) of the monomeric subunits, which determine the five‐fold and quasi‐six‐fold symmetry contacts of the VLPs. In order to reduce the stability of Qβ VLPs, we mutationally converted the amino acid stretch 76‐ANGSCD‐81 within the FG loop into the 76‐VGGVEL‐81 sequence. It led to production in Escherichia coli cells of aberrant rod‐like Qβ VLPs, along with normal icosahedral capsids. The length of the rod‐like particles exceeded 4–30 times the diameter of icosahedral Qβ VLPs.
Intervirology | 2002
Paul Pumpens; Raimundas Razanskas; Peter Pushko; Regina Renhof; Indulis Gusars; Dace Skrastina; Velta Ose; Galina Borisova; Irina Sominskaya; Ivars Petrovskis; Juris Jansons; Kestutis Sasnauskas
Objectives: In an attempt to develop virus-like particles (VLPs) as experimental vaccine against human papilloma virus (HPV)-induced tumours, the HPV16 E7 oncoprotein epitopes spanning amino acid (aa) residues 35–98 were expressed on three proteins capable of VLP formation: hepatitis B virus (HBV) surface (HBs) and core (HBc) antigens, and RNA phage fr coats (frCP). Methods: The profile of immunoglobulin isotypes induced in Balb/C mice after immunization with purified chimeric proteins was studied. Results: The HBs*-E7(35–54) protein expressing E7 residues 35–54 between residues 139 and 142 of the HBs carrier formed HBs-like particles in Saccharomyces cerevisiae. The HBcΔ-E7(35–98), but not the frCP-E7(35–98), ensured VLP formation in Escherichia coli. In Balb/C mice, the HBs*-E7(35–54) VLPs predominantly induced an anti-E7 antibody, but not anti-HBs carrier response, whereas the HBcΔ-E7(35–98) VLPs induced a lower anti-E7 compared to anti-HBc carrier response. The frCP-E7(35–98) protein elicited equally high antibody responses to both E7 and frCP carrier. Analysis of the immunoglobulin G isotype profile of the antibodies induced by the E7-carrying chimeras showed that the HBs and frCP derivatives were capable of eliciting the Th1 and Th2 subsets of T helper cells, whereas the HBc-derived chimeras elicited only the Th2 subset. Conclusions: The HBs and HBc, but not frCP carriers support an efficient outcome for VLPs carrying the HPV16 E7 epitopes. All chimeric proteins may be regarded as potential vaccine candidates.
Intervirology | 1996
Galina Borisova; O.B. Borschukova Wanst; Mezule G; Dace Skrastina; Ivars Petrovskis; Andris Dislers; Pauls Pumpens; Elmars Grens
Spatial and immunochemical elucidation of hepatitis B core antigen suggested unique organization of its major immunodominant region (MIR) localized within the central part of molecule around amino acid residues 74-83. This superficial loop was recognized as the most prospective target for the insertion of foreign epitopes ensuring maximal antigenicity and immunogenicity of the latter. MIR allowed a substantial capacity of insertions up to about 40 amino acid residues without loss of the capsid-forming ability of core particles. Vector capacity as well as structural behavior and immunological fate of inserted epitopes were dependent on their primary structure. Special sets of display vectors with retained but cross-sectioned MIR as well as with uni- and bidirectionally shortened MIR have been investigated.
Intervirology | 2002
Andris Kazaks; Sylvie Lachmann; Diana Koletzki; Ivars Petrovskis; Andris Dislers; Velta Ose; Dace Skrastina; Hans R. Gelderblom; Åke Lundkvist; Helga Meisel; Galina Borisova; Detlev H. Krüger; Paul Pumpens; Rainer Ulrich
In recent years, epitopes of various origin have been inserted into the core protein of hepatitis B virus (HBc), allowing the formation of chimeric HBc particles. Although the C-terminus of a C-terminally truncated HBc (HBcΔ) tolerates the insertion of extended foreign sequences, the insertion capacity is still a limiting factor for the construction of multivalent vaccines. Previously, we described a new system to generate HBcΔ mosaic particles based on a read-through mechanism in an Escherichia coli suppressor strain [J Gen Virol 1997;78:2049–2053]. Those mosaic particles allowed the insertion of a 114-amino acid (aa)-long segment of a Puumala hantavirus (PUUV) nucleocapsid (N) protein. To study the value and the potential limitations of the mosaic approach in more detail, we investigated the assembly capacity of ‘non-mosaic’ HBcΔ fusion proteins and the corresponding mosaic constructs carrying 94, 213 and 433 aa of the hantaviral N protein. Whereas the fusion proteins carrying 94, 114, 213 or 433 aa were not assembled into HBcΔ particles, or only at a low yield, the insertion of a stop codon-bearing linker restored the ability to form particles with 94, 114 and 213 foreign aa. The mosaic particles formed exhibited PUUV-N protein antigenicity. Immunization of BALB/c mice with these mosaic particles carrying PUUV-N protein aa 1–114, aa 1–213 and aa 340–433, respectively, induced HBc-specific antibodies, whereas PUUV-N protein-specific antibodies were detected only in mice immunized with particles carrying N-terminal aa 1–114 or aa 1–213 of the N protein. Both the anti-HBc and anti-PUUV antibody responses were IgG1 dominated. In conclusion, stop codon suppression allows the formation of mosaic core particles carrying large-sized and ‘problematic’, e.g. hydrophobic, hantavirus sequences.
Vaccine | 2006
Marija Mihailova; Mechthild Boos; Ivars Petrovskis; Velta Ose; Dace Skrastina; Melanie Fiedler; Irina Sominskaya; Stefan Ross; Paul Pumpens; Michael Roggendorf; Sergei Viazov
Virology | 2004
Astrid Geldmacher; Dace Skrastina; Ivars Petrovskis; Galina Borisova; John Berriman; Alan M. Roseman; R. Anthony Crowther; Jan Fischer; Shamil Musema; Hans R. Gelderblom; Åke Lundkvist; Regina Renhofa; Velta Ose; Detlev H. Krüger; Paul Pumpens; Rainer G. Ulrich
Vaccine | 2005
Astrid Geldmacher; Dace Skrastina; Galina Borisova; Ivars Petrovskis; Detlev H. Krüger; Paul Pumpens; Rainer G. Ulrich
Protein Expression and Purification | 2006
Marija Mihailova; Melanie Fiedler; Mechthild Boos; Ivars Petrovskis; Irina Sominskaya; Michael Roggendorf; Sergei Viazov; Paul Pumpens
Archive | 2013
Renate Ranka; Ivars Petrovskis; Irina Sominskaya; Janis Bogans; Ruta Bruvere; Inara Akopjana; Velta Ose; Irena Timofejeva; Kalvis Brangulis; Pauls Pumpens; Viesturs Baumanis